Company Overview and News

2
Boralex, Invenergy Ontario clean-power projects hit by Ford

13h thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BAMGF H BRLXF NPIFF BAMKF HRNNF BAM TERP NPI

1
Canadian Small Caps: Picks, Performance, Portfolio

22h seekingalpha
There are compelling reasons to pick your own stocks here, but this requires more discipline and honesty than when buying an exchange traded fund.
TTTGF FXFLF FXFHF FAXXF MEQYF FRFHF FRFFF MRCBF FRFZF GCM.WT.A FAXRF FRFXF AOCIF BAM CDPYF BAMGF TPWRF VRRKF FRFGF TPRFF MIC GMICF GCM BAMKF TTR

1
Brookfield Asset Management 2018 Second Quarter Results Conference Call And Webcast

2018-07-13 globenewswire
Second Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2018 Second Quarter Conference Call & Webcast on Thursday, August 9, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives.
BAMGF BAMKF BAM

2
Kushner’s Firm Deepens Ties to Those With Business in Washington - The New York Times

2018-07-11 nytimes
Eighteen months into Jared Kushner’s White House tenure, his family’s real estate firm is deepening its financial relationships with institutions and individuals that have a lot riding on decisions made by the federal government.
BAMGF NYTAB BAMKF BAM

2
Brookfield Business Partners L.P. 2018 Second Quarter Conference Call and Webcast for Investors and Analysts

2018-07-11 globenewswire
BROOKFIELD NEWS, July 11, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Business Partners’ (TSX:BBU.UN) (NYSE:BBU) 2018 Second Quarter Conference Call & Webcast on Friday, August 3, 2018 at 9:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives.
BAMGF BBU BAMKF BAM

139
My 'Ten Commandments' Of Investing

2018-07-11 seekingalpha
In this letter, I wish to share with you our investment strategy and summarize for you the logic behind our investment activities.
BAMGF NNUTU NNUTD CALL RAD AGO BAMKF BAM

2
Brookfield in talks with Altico Capital shareholders to buy stake

2018-07-11 livemint
Mumbai: Canadian alternative assets manager Brookfield Asset Management is in talks with shareholders of Mumbai-based Altico Capital to acquire a significant stake in the non-banking financial company (NBFC), two people aware of the development said on condition of anonymity. According to the people cited above, the proposed investment will be a mix of primary and secondary investment, and may lead to the exit of Varde Partners, one of the shareholders in Altico.
BAMGF ICICIBANK 532174 IBN BAMKF BAM SBAZ

5
3 High-Yield Blue Chips That Could Make You Rich

2018-07-10 seekingalpha
The midstream industry is one of the most despised on Wall Street and is now in its fourth year of a bear market.
BAMGF ENBBF EBGUF XOM ENB EPD SEP ENB EBBNF BIP EEP MMP BAMKF BAM

1
GGP: Weighing The Brookfield Deal

2018-07-09 seekingalpha
This is a complicated deal with numerous pros and cons, but worth of examination and consideration.
BAMGF BAMKF BAM

11
A Primer On Brookfield Asset Management

2018-07-09 seekingalpha
Brookfield (BAM), an under-the-radar company, is one of the largest alternative asset managers in the world.
BAMGF ADN BPY BBU SDSNQ ACAZF GGP.PRA SUNE BRK.A SUNEQ GLBL BIP GGP BAMKF BAM MKL TERP BEP

2
Brookfield Property Partners' Debt Is A Bit Too High For Me

2018-07-09 seekingalpha
BPY has a proven growth plan backed by a proven sponsor and trades at an attractive valuation.
BAMGF BPY BAMKF BAM

7
5 Reasons Brookfield Infrastructure Partners Might Be The World's Best High-Yield Stock

2018-07-08 seekingalpha
Brookfield Infrastructure Partners has crushed most other utilities and the S&P 500 over the past decade.
BAMGF ENBBF ENB 532712 NEE.PRI ENB BRK.A NEE.PRJ RCOM NEE.PRC NEE.PRQ NEE.PRR EBBNF BIP BAMKF BAM NEE

93
CANADA STOCKS-TSX rises as financials gain from strong jobs data

2018-07-06 reuters
(Reuters) - Canada’s main stock index edged higher on Friday as financial stocks gained after a strong domestic jobs data cemented expectations of fourth interest rate hike of the year next week.
BAMGF RCI ACBFF TCLAF CG CGEAF TCLCF CGC BCE CAGDF RCIAF TWMJF ACB WEED BAMKF BAM

4
A Millennial's Retirement Planning Journey (Q2 '18)

2018-07-04 seekingalpha
Beginning to save for retirement at a young age is highly beneficial and significant long-term wealth can be generated with low monthly investment.
BAMGF FB PEGI AMT.PRB AMT.PRA ENB ENB AMT PEG BIP BAMKF BAM CSUWF

4
CANADA STOCKS-TSX rises, boosted by Enbridge and financial shares

2018-07-04 reuters
TORONTO, July 4 (Reuters) - Canada’s main stock index edged higher on Wednesday, helped by gains for heavily-weighted financial shares and Enbridge Inc after the company said it would sell natural gas assets.
BAMGF ENBBF KML ACBFF ENB NMKEF ENB ACB NMX BDRPF EBBNF BIP BAMKF BAM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

6h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 112585954